Trial Profile
A Phase 2a Study of the Safety, Tolerability, and Pharmacodynamic Effects of Pexidartinib in Subjects with Mild to Moderate Alzheimer's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2019
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Plexxikon
- 04 Jul 2019 Status changed from suspended to discontinued.
- 04 Aug 2017 New trial record